Transcriptional dysregulation during myeloid transformation in AML.
about
Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasmsGenomics-based Approach and Prognostic Stratification Significance of Gene Mutations in Intermediate-risk Acute Myeloid LeukemiaC/EBP and DEK coordinately regulate myeloid differentiationCCAAT/enhancer-binding proteins (C/EBP)-α and -β are essential for ovulation, luteinization, and the expression of key target genesDifferentiation therapy of leukemia: 3 decades of development.The oncoprotein EVI1 and the DNA methyltransferase Dnmt3 co-operate in binding and de novo methylation of target DNA.The leukemogenic t(8;21) fusion protein AML1-ETO controls rRNA genes and associates with nucleolar-organizing regions at mitotic chromosomes.The tumour-suppressive miR-29a/b1 cluster is regulated by CEBPA and blocked in human AML.Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features.Long-term follow-up of cytogenetically normal CEBPA-mutated AMLHuman germline and pan-cancer variomes and their distinct functional profilesC/EBPα and MYB regulate FLT3 expression in AMLTransformation by Tribbles homolog 2 (Trib2) requires both the Trib2 kinase domain and COP1 bindingC/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutationsAdvances in molecular genetics and treatment of core-binding factor acute myeloid leukemiaThe human SWI/SNF complex associates with RUNX1 to control transcription of hematopoietic target genesCharacterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.Gene mutations and molecularly targeted therapies in acute myeloid leukemia.Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cells.Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technologyThe molecular basis of myeloid malignancies.Dominant-negative mechanism of leukemogenic PAX5 fusions.Proteomic discovery of MNT as a novel interacting partner of E3 ubiquitin ligase E6AP and a key mediator of myeloid differentiation.C/EBPα-p30 protein induces expression of the oncogenic long non-coding RNA UCA1 in acute myeloid leukemiaDetection of CEBPA double mutants in acute myeloid leukemia using a custom gene expression arrayDysregulation of the C/EBPalpha differentiation pathway in human cancer.The role of aberrant transcription factor in the progression of chronic myeloid leukemia.Current findings for recurring mutations in acute myeloid leukemiaGenetic biomarkers in acute myeloid leukemia: will the promise of improving treatment outcomes be realized?Gfi-1 inhibits proliferation and colony formation of p210BCR/ABL-expressing cells via transcriptional repression of STAT 5 and Mcl-1.Shwachman-Bodian-Diamond syndrome (SBDS) protein deficiency impairs translation re-initiation from C/EBPα and C/EBPβ mRNAsA novel crosstalk between TLR4- and NOD2-mediated signaling in the regulation of intestinal inflammation.CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.Downregulation of RUNX1 by RUNX3 requires the RUNX3 VWRPY sequence and is essential for Epstein-Barr virus-driven B-cell proliferationC/EBPalpha or C/EBPalpha oncoproteins regulate the intrinsic and extrinsic apoptotic pathways by direct interaction with NF-kappaB p50 bound to the bcl-2 and FLIP gene promoters.Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis.Editorial: granulopoiesis versus monopoiesis: a consequence of transcription factors dancing with the right partners.Clinical Assessment and Diagnosis of Germline Predisposition to Hematopoietic Malignancies: The University of Chicago Experience.Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia.
P2860
Q24595117-D67DA44B-1651-4D30-AF0B-D864F74DA054Q26796514-2D46DF8F-2B94-4A65-94FA-9CA2C2E30787Q29041284-0C8A58E1-DB86-4586-B175-0832E65EFF7EQ30426060-A036B44F-8309-48C1-A19A-35AC7F3E8BF9Q33409795-41576C2C-68A8-49BB-A826-1E69F006085BQ33939478-F48ED75D-3762-4A02-859D-8A266A3C8EBEQ33995514-733B3A0B-2737-458F-BAB3-476353AA2EB8Q34005915-BABDC97A-E827-4A6E-8ECD-D0F2C7B64883Q34156717-AD188A97-91CB-47FA-9A20-66E9A0675B9FQ34233639-62F20074-6A1A-4530-A512-85AC7844F68EQ34312953-DE5EE4FB-68C8-470A-815B-ABFFACA6AE14Q34425939-EB948DD3-0CEF-4EC2-BE6A-2746D302AD9AQ34450702-0ABD58AA-3CAD-4236-80AC-FA1BEF4F5A96Q34541735-647F86E0-3B60-4DF7-9C22-6FF0ADEA61A6Q34598109-8C218947-EA64-47B6-9BF1-14725C9352FEQ34606841-3558F45A-311E-465A-83B0-67B44276FDE2Q34612599-AF6961A7-1FE8-4A8E-8F4C-F52969EF7621Q34647741-7D788F24-BE48-4954-8C57-87146F78F222Q34930673-FB508D92-1455-47D5-91BA-AB2996DC1813Q35040064-6E79CA53-C419-4463-BBFC-DF2E73033A2FQ35083685-0A81D733-F09F-4AD8-9377-C5767DE6EFC1Q35103708-F18873FC-7377-4889-A2EA-E3A51623D952Q35402092-0933D6F0-7961-42A9-AE2C-12F3223AFD27Q35823073-18ED6ECC-3720-41AD-A6C4-4A7E381DBEE5Q36210927-F0D25D36-90D5-40F3-AD8F-F25CEAEBF62EQ36789391-A9332F37-E385-47C5-BBB8-A5C00C62DB32Q37104787-FABAC6BE-B40B-4F07-AFF1-E79C1C4431D4Q37259355-CA2A0211-7D3E-440D-8068-D381B4096A83Q37932085-24AD2FB2-CCEA-4A69-8431-D2C1FB64F5B6Q38044773-52690891-2B25-45A3-9C5C-B4B962786DADQ38328207-83BA0FC9-FEAE-41C8-88CC-341F3CD0887CQ38804023-2BB737E8-0B92-4AF8-933B-E0AF95869458Q38855496-26E1C029-827F-4247-AE0F-AE1C578E5215Q38884580-E2718149-33FB-4984-86E1-EB69F952397BQ39858777-4FCF4F8D-3FE4-4B6A-9664-25D0FB8FD12DQ41839749-C4C9B855-E0C4-4D55-8227-DEFED7E375E7Q42113668-587F56E3-1BF5-4B99-A05E-D5C9F3A5C8C3Q42919224-0F1D8A75-BF67-45DA-B471-ABBA357F43F8Q47128524-2130CB12-0715-4E68-92F3-EBFA88910E13Q54374972-2A7692CB-BA64-4ABD-9EE2-135410B22274
P2860
Transcriptional dysregulation during myeloid transformation in AML.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Transcriptional dysregulation during myeloid transformation in AML.
@en
type
label
Transcriptional dysregulation during myeloid transformation in AML.
@en
prefLabel
Transcriptional dysregulation during myeloid transformation in AML.
@en
P2860
P356
P1433
P1476
Transcriptional dysregulation during myeloid transformation in AML.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.ONC.1210765
P407
P577
2007-10-01T00:00:00Z
P5875
P6179
1050056036